

MAR 3.1 2008 BY

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission

Application Number	10/524,945
Filing Date	February 16, 2005
First Named Inventor	Farhad Parhami
Art Unit	1633
Examiner Name	M.G. Leavitt
Attorney Docket Number	58086-241892

ENCLOSURES (Check all that apply)								
X Fee Transm	nittal Form	Drawing(s)		After Allowance Communication to TC				
Fee A	ttached	Licensing-related Papers		Appeal Communication to Board of Appeals and Interferences				
	to Restriction nt (3 pages)	Petition		Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)				
After F	Final	Petition to Convert to a Provisional Application		Proprietary Information				
Affida	vits/declaration(s)	Power of Attorney, Revocation Change of Correspondence		Status Letter				
Extension of	f Time Request	Terminal Disclaimer		Other Enclosure(s) (please Identify below):				
Express Aba	andonment Request	Request for Refund						
Information	Disclosure Statement	CD, Number of CD(s)						
Certified Co Document(s	py of Priority 3)	Landscape Table on CD						
Reply to Mis		Remarks		· · · · · · · · · · · · · · · · · · ·				
	to Missing Parts under R 1.52 or 1.53							
	SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT							
Firm Name	VENABLE LLP	1 -						
Signature								
Printed name	Lars H. Genieser							
Date	March 31, 2008		Reg. No.	46,722				



Effective on 12/08/2004. Fees pursuant to the Consolidated Appropriations Act, 2005 (H.R. 4818).			Complete if Known							
					10/524,945					
FEE TRANSMITTAL			Filing Date		February 16, 2005					
For FY 2008			First Named Inv Examiner Name		arhad Parhar M.G. Leavitt	nı				
Applicant cl	aims small entity state	IS See 37 CER 1 27								
Applicant claims small entity status. See 37 CFR 1.27 TOTAL AMOUNT OF PAYMENT (\$) 0.00			Art Unit 1633 Attorney Docket No. 58086-241892							
		(\$) 0.00		Attorney Docket	10. 56086-241692					
METHOD OF P	AYMENT (check	all that apply)								
Check Credit Card Money Order None Other (please identify):										
X Deposit Accou	int Deposit Account f	Number: 22-0	261	Deposit /	Account Name	. Ve	nable LLP			
For the ab	ove-identified depo	sit account, the Dir	ector is	hereby authorize	d to: (chec	k all that apply)				
ı <u></u>	ge fee(s) indicated			<u></u>	e fee(s) ind	icated below, ex	xcept for th	e filing fee		
	ge any additional f) under 37 CFR 1.	ee(s) or underpaym 16 and 1.17	nents o	f x Credit	any overpa	yments				
FEE CALCULA	TION					•				
1. BASIC FILING,	SEARCH, AND E	KAMINATION FEE	S							
	FII	ING FEES	SE	ARCH FEES	EXAMIN	ATION FEES				
Application Type	Fee (\$	Small Entity) Fee (\$)	Fee (\$	Small Entity Fee (\$)	Fee (\$)	Small Entity Fee (\$)	Fees P	aid (\$)		
Utility	310	155	510	255	210	105	rees r	aiu (4)		
Design	210	105	100	50	-130	65				
Plant	210	105	310	155	160	80	-			
Reissue	_									
	310	155	510	255	620	310				
Provisional	210	105	0	. 0	0	0				
2. EXCESS CLAIN	I FEES						Fee (\$)	Small Entity Fee (\$)		
Fee Description Each claim over 2	0 (including Reiss	ues)					50	25		
Each independent							210	105		
Multiple depender		,					370	185		
Total Claims	Extra Claims	Fee (\$)	Fee F	Paid (\$) M		Iltiple Depende				
-	= ,			· · · · · · · · · · · · · · · · · · ·	Fee (\$)		Fee Paid (\$))		
HP = highest number	of total claims paid for							•		
Indep. Claims	Extra Claims	Fee (\$)	Fee I	Paid (\$)				_		
HP = highest number	of independent claims	paid for, if greater than	3.							
HP = highest number of independent claims paid for, if greater than 3. 3. APPLICATION SIZE FEE										
		ceed 100 sheets of								
		the application size			or small en	tity) for each a	dditional 50	1		
		5 U.S.C. 41(a)(1)(_			
<u>Total Sheets</u>	Extra Sheet			dditional 50 or frac			Fee P	<u>'aid (\$)</u>		
				(round up to a who	le number)	x	=			
4. OTHER FEE(S) Fees Paid (\$)										
Other (e.g., late filing surcharge):										
SUBMITTED BY	1. 91	// -								
Signature				Registration No. (Attorney/Agent)	46,722	Telephone	(202) 344	-4000		
Name (Print/Type) Lars H. Genieser						Date	March 31	, 2008		

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application:

Farhad PARHAMI

U.S. Application No.: 10/524,945

Confirmation No.: 3129

Filed: February 16, 2005

Title: AGENTS AND METHODS FOR

ENHANCING BONE FORMATION

Art Unit:

1633

Examiner:

Maria Gomez LEAVITT

Atty. Dkt. No.: 58086-241892

Customer No.

RESPONSE TO RESTRICTION REQUIREMENT

Assistant Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

This is a response to the Restriction Requirement dated February 28, 2008, providing for a response time of one month or 30 days, whichever is longer. Applicants, by their attorneys, respond to the Restriction Requirement of February 28, 2008 by electing without traverse as follows.

Remarks and Election in Response to the Restriction Requirement

For clarity, Applicants reiterate the Examiner's view of distinct inventions as expressed in the Restriction Requirement of February 28, 2008:

Group I.

Claims 1-28;

Group II.

Claims 29-36;

Group III.

Claims 37-40;

Group IV.

Claim 41.

Applicants elect Group I, i.e., claims 1-28, without traverse.

In response to the Examiner's requirement in item 1) on page 5 of the Restriction Requirement to elect a species of oxysterol for claims 2, 7, 14, 16, 20, and 25, Applicants elect 20S-hydroxycholesterol without traverse. Applicants note that the term "20S-hydroxycholesterol" is synonymous with the term "20α hydroxycholesterol". Claims 2, 7, 14, 16, 20, and 25 encompass the elected species, 20S-hydroxycholesterol.

In response to the Examiner's requirement in item 2) on pages 5-6 of the Restriction Requirement to elect a species of a combination of oxysterols for claims 3, 8, 17, 21, and 26, Applicants elect the combination of 20S-hydroxycholesterol and 22S-hydroxycholesterol without traverse. Claims 3, 8, 17, 21, and 26 encompass the elected species, the combination of 20S-hydroxycholesterol and 22S-hydroxycholesterol.

In response to the Examiner's requirement in item 3) on page 6 of the Restriction Requirement to elect a species of secondary agent for claims 4, 5, 9, 10, 18, 22, 23, 27, and 28, Applicants elect bisphosphonates without traverse. At least claims 23 and 28 encompass the elected species, bisphosphonates.

In response to the Examiner's requirement in item 4) on page 7 of the Restriction Requirement to elect a species of biological marker for claim 11, Applicants elect expression of osteocalcin mRNA without traverse. Claim 11 encompasses the elected species, expression of osteocalcin mRNA.

In response to the Examiner's requirement in item 5) on pages 7-8 of the Restriction Requirement to elect a species of mammalian cells for claim 12, Applicants elect osteoprogenitor cells without traverse. Claim 12 encompasses the elected species, osteoprogenitor cells.

Although this election is made without traverse, Applicants specifically reserve the right to rejoinder of the claims of Groups II, III, and IV and withdrawal of the Restriction Requirement upon allowance of a claim of Group I and amendment of the claims of Groups II, III, and IV to include all limitations of the allowed claim, pursuant to MPEP § 821.04.

Appl. No. 10/524,945 Reply to Restriction Requirement of February 28, 2008

Applicants respectfully request that a Notice of Allowance of claims 1-28 be timely issued in this case.

No fee is believed to be necessary in connection with the filing of this Response. However, any fee deficiency is hereby authorized to be charged, or any overpayment credited, to Deposit Account No. 22-0261.

Respectfully submitted,

Dated: March 31, 2008

Lars H. Genieser

Registration No. 46,722

VENABLE LLP P.O. Box 34385

Washington, D.C. 20043-9998

Telephone: (202) 344-4000 Telefax: (202) 344-8300

LHG

DC2/943701